Endo K
Department of Nuclear Medicine, Gunma University School of Medicine, Maebashi, Japan.
Gan To Kagaku Ryoho. 1999 May;26(6):744-8.
Radionuclides have been used for the diagnosis and therapy of cancers. In Japan, about 1.8 million studies are performed annually, especially on bone, the heart, the brain and cancer. In contrast to anatomical studies with X-ray, US or CT, nuclear medicine provides physiological or metabolic images. The characteristics of nuclear medicine come from the use of tracer studies employing various radiopharmaceuticals. The most commonly used radionuclides for cancer studies are 67Ga and 201T1. Recently, however, many other radiopharmaceuticals with tumor specificity have been developed, such as 99mTc labeled monoclonal antibodies and 111In labeled octreotide. 18F-FDG, which images glucose metabolism, is very useful in the management of lung, colorectal and other cancers. Furthermore, radionuclides are also employed in the therapy of cancer, such 131I-labeled anti-CD20 antibody for the B-cell lymphoma and 89Sr for the palliation of bone pain caused by prostate and breast cancer metastases.
放射性核素已被用于癌症的诊断和治疗。在日本，每年大约进行180万项研究，尤其针对骨骼、心脏、大脑和癌症。与使用X射线、超声或CT进行的解剖学研究不同，核医学提供生理或代谢图像。核医学的特点源于使用各种放射性药物进行示踪研究。癌症研究中最常用的放射性核素是67Ga和201T1。然而，最近已经开发出许多其他具有肿瘤特异性的放射性药物，如99mTc标记的单克隆抗体和111In标记的奥曲肽。18F-FDG可成像葡萄糖代谢，在肺癌、结直肠癌和其他癌症的管理中非常有用。此外，放射性核素也用于癌症治疗，如用于B细胞淋巴瘤的131I标记抗CD20抗体和用于缓解前列腺癌和乳腺癌转移引起的骨痛的89Sr。
